Hexagon Nutrition IPO 2026

Hexagon Nutrition's ₹138.87 crore mainboard IPO is one of the smallest mainboard offerings of FY27 — and a pure OFS, with no fresh capital reaching the operating company. That structural setup determines most of what investors need to think about. The business itself is unusual: a 30-year-old nutrition specialist with a B2B-heavy revenue mix (institutional premix supply to global food manufacturers, RUTF / RUSF tenders to UN agencies, branded clinical nutrition through hospital channels). This is not Britannia or Tata Consumer — it's a specialty-ingredient + humanitarian-nutrition operator. The closest legitimate comparable is probably the unlisted nutrition-ingredient players, not branded-FMCG names. Investors benchmarking ₹45 against Britannia's P/E will reach the wrong conclusion. Fundamentals from FY24-FY25: revenue grew from ₹305 crore to ₹331 crore (~9% YoY) and PAT doubled from ₹12 crore to ₹24 crore — meaningful operating-leverage expansion. PAT margin at ~7.25% is healthy for an institutional-supply business model, though materially below branded-FMCG peers (Britannia operates around 12-14%). The margin gap is structural — institutional B2B contracts are price-disciplined by tender economics — and is unlikely to close to FMCG-leader levels. What the pricing implies: ₹42-45 price band against FY25 PAT of ₹24 crore translates to a P/E in the 50-60x range depending on total share count post-listing (RHP-specific number not yet sourced at publication). That's well above FMCG-peer averages and demands either continued PAT acceleration or a re-rating thesis specific to nutrition-ingredient scarcity. Neither is obvious from the publicly available material at this stage. The pure-OFS structure is the biggest negative signal. Existing shareholders are exiting at what they view as a fair price; the operating business gets nothing new to deploy. For Hexagon to justify a 50-60x P/E, it needs RUTF / RUSF tender wins, premix capacity expansion (Tashkent ramp), and margin progression — none of which the IPO proceeds will fund. Whatever growth happens has to come from existing internal accruals and operating cash flow. The issue is small enough (₹138.87 cr is tiny relative to mainboard liquidity floor of ~₹500 cr) that subscription dynamics will be dominated by retail and small institutional flows rather than large mutual-fund interest. Listing-day behaviour for sub-₹150 cr mainboard issues has been volatile through 2026 — either 15-25% listing pops on supply scarcity or muted debuts when QIB demand is thin. The price-band wedge (₹42 lower vs ₹45 upper is a 7% range) leaves room for partial subscription if institutional demand is weak. Neutral call for now. Wait for anchor allocation list on 4 June and bookbuild day-1 institutional response before committing. If anchor amount exceeds ₹40 crore (30%+ of issue) with marquee mutual fund names, upgrade to selective subscribe at lower band. If anchor is thin and dominated by smaller institutional names, the listing risk is asymmetric — flat-to-negative open is plausible. Listing-gain hunters should size positions modestly; structural-hold investors should wait for the first listed-quarter results to evaluate margin trajectory.